Cargando…
Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing
Autores principales: | Harrigan, James J., Hubbard, Rebecca A., Thomas, Sunil, Riello, Ralph J., Bange, Erin, Mamtani, Mira, Mamtani, Ronac |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295147/ https://www.ncbi.nlm.nih.gov/pubmed/32542496 http://dx.doi.org/10.1007/s11606-020-05938-4 |
Ejemplares similares
-
Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
por: Parikh, Ravi B., et al.
Publicado: (2023) -
Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic
por: Rome, Benjamin N., et al.
Publicado: (2021) -
Investigation of factors influencing inpatient antibiotic prescribing decisions in the Veterans’ Health Administration
por: Economos, Evan T., et al.
Publicado: (2022) -
Accuracy of a Text Intervention to Minimize the Burden of Cancer Care Among Patients Treated With Immune Checkpoint Inhibitors
por: Bange, Erin M., et al.
Publicado: (2022) -
Decreased antimicrobial prescribing rate following academic detailing of resident physicians in outpatient clinic
por: Andrews, Shannon L., et al.
Publicado: (2023)